Oncology treatments dominated the world drug pipeline in 2017 but struggled to make the transition from clinical trials to market, a new analysis by Tufts University’s Center for the Study of Drug Development finds...

Protecting Confidential Information in Clinical Trial Agreements

When setting the terms for working with trial sites, sponsors must be sure to protect their intellectual property. Typically, this appears as a unilateral obligation on the part of the institution to protect the confidential information it receives from the sponsor. It is in the sponsor’s best interest to ensure the agreed-upon definition of “confidential information” is broad enough to safeguard the investments it has made in connection with the study...

• Regulatory Update
• FDA Actions